Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy
JM Benito, M López, S Lozano… - JAIDS Journal of …, 2005 - journals.lww.com
JM Benito, M López, S Lozano, C Ballesteros, P Martinez, J González-Lahoz, V Soriano
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2005•journals.lww.comBackground: Immune activation is an independent surrogate marker of CD4 T-cell depletion
in HIV-infected patients. Highly active antiretroviral therapy (HAART) reduces disease
progression as a direct consequence of suppressing HIV replication. Immune function does
not normalize completely in most subjects on HAART, however, perhaps reflecting residual
HIV replication. So far, it is unclear to what extent immune activation may influence the
evolution of CD4 T-cell counts in patients on HAART. Patients and Methods: The expression …
in HIV-infected patients. Highly active antiretroviral therapy (HAART) reduces disease
progression as a direct consequence of suppressing HIV replication. Immune function does
not normalize completely in most subjects on HAART, however, perhaps reflecting residual
HIV replication. So far, it is unclear to what extent immune activation may influence the
evolution of CD4 T-cell counts in patients on HAART. Patients and Methods: The expression …
Abstract
Background:
Immune activation is an independent surrogate marker of CD4 T-cell depletion in HIV-infected patients. Highly active antiretroviral therapy (HAART) reduces disease progression as a direct consequence of suppressing HIV replication. Immune function does not normalize completely in most subjects on HAART, however, perhaps reflecting residual HIV replication. So far, it is unclear to what extent immune activation may influence the evolution of CD4 T-cell counts in patients on HAART.
Patients and Methods:
The expression of CD38 on naive and memory subsets of CD4+ and CD8+ T cells was measured quantitatively by flow cytometry in 62 drug-naive HIV-positive and 30 HIV-uninfected controls. In addition, the evolution of this marker as well as that of some virologic parameters (plasma viremia and proviral load) and CD4 counts were assessed in 25 HIV-infected individuals who initiated HAART and were followed for 12 months.
Results:
The mean level of CD38 on memory CD4+ and CD8+ T cells as well as in naive CD8+ cells was significantly higher in drug-naive HIV-positive subjects than in HIV-negative controls. Moreover, it was highly correlated with viral load titers. In patients on successful HAART, immune activation declined in all T-cell subsets, particularly among memory CD8+ cells. It remained elevated with respect to HIV-negative controls, however, even after 12 months of HAART. There was a significant correlation between the CD8+ T-cell activation decay and the increase of CD4+ T cells on HAART. Patients with the highest decline in CD8 activation were those showing the highest CD4 T-cell gains after 12 months of therapy.
Conclusions:
The level of CD38 expression on different T-cell subsets is differentially upregulated in drug-naive HIV-infected patients. After successful HAART, immune activation decreases in all T-cell subsets, although it still remains elevated in most cases after 12 months of HAART. The extent of immune deactivation under successful HAART correlates with the ability to reconstitute CD4 counts.
Lippincott Williams & Wilkins